- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01051323
An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Renal Anemia
17 de noviembre de 2015 actualizado por: Hoffmann-La Roche
Non-interventional Study to Investigate Hemoglobin Levels and Dose Over Time in the Daily Use of Mircera for Renal Anemia in Larger Centers, and to Detect Differences Between Standard of Care in the Centers
This observational study will investigate hemoglobin levels and Mircera (methoxy polyethyleneglycol-epoetin beta) dose over time in patients with chronic kidney disease, and compare standards of care between centers.
Data from each patient will be collected over 12 months of Mircera therapy.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Tipo de estudio
De observación
Inscripción (Actual)
1580
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
-
Saarlouis, Alemania, 66740
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Método de muestreo
Muestra de probabilidad
Población de estudio
CKD patients treated with Mirecera at different medical centers
Descripción
Inclusion Criteria:
- adult patients, >/= 18 years of age
- chronic kidney disease
- informed consent for data transmission
Exclusion Criteria:
- serious hematological or infectious disease
- acute bleeding in the 16 weeks preceding data collection
- participation in an interventional trial
- female patients: pregnancy or breast-feeding
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
---|---|
1
|
As prescribed by physician
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Percentage of Participants With at Least One Hemoglobin Value Outside the Target Range
Periodo de tiempo: Month 0 to Month 12
|
Mean hemoglobin was calculated from measurements taken during the Evaluation Period (Month 0 to Month 12).
The target hemoglobin range was 10 to 13 gram/deciliter (g/dL).
Percentage of participants with at least one hemoglobin value less than (<) 10 g/dL or greater than (>) 13 g/dL during the evaluation period by predialysis/hemodialysis is presented.
|
Month 0 to Month 12
|
Percentage of Participants With Hemoglobin Values Within Pre-defined Ranges During Evaluation Period by Dose Modification, Age, and Center Size
Periodo de tiempo: Month 0 to Month 12
|
The percentage of participants with hemoglobin (Hb) values within the pre-defined ranges (10-12 g/dL, 11-12 g/dL, and 11-13 g/dL) during evaluation period (Month 0 to Month 12) by dose modification (yes or no), age (<65 years, greater than or equal to [>=] 65 years) and center size (>100 participants, less than or equal to [<=] 100 participants) is presented.
|
Month 0 to Month 12
|
Percentage of Participants With Hemoglobin Values Within Pre-defined Ranges During Month 6 to Month 12 by Dose Modification, Age, and Center Size
Periodo de tiempo: Month 6 to Month 12
|
The percentage of participants with hemoglobin values within the pre-defined ranges (10-12 g/dL, 11-12 g/dL, and 11-13 g/dL) during Month 6 to Month 12 by dose modification (yes or no), age (<65 years, >=65 years) and center size (>100 participants, <=100 participants) is presented.
|
Month 6 to Month 12
|
Maximum Intra-Individual Fluctuation of Hemoglobin Values by Predialysis/Hemodialysis, Age, and Center Size
Periodo de tiempo: Month 0 to Month 12
|
For characterization of intra-individual fluctuations, the maximum absolute differences were derived from study period specific individual mean values.
Maximum intra-individual fluctuation of hemoglobin values by predialysis/hemodialysis, age (<65 years, >=65 years), and center size (>100 participants, <=100 participants) is presented.
Data for this outcome measure was reported for overall participants.
|
Month 0 to Month 12
|
Serum Ferritin Values
Periodo de tiempo: Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
|
Serum ferritin levels were measured as nanogram/milliliter (ng/mL).
Data for this outcome measure was reported for overall participants.
|
Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
|
Serum Iron Values
Periodo de tiempo: Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
|
Serum iron levels were measured as microgram/deciliter (mcg/dL).
Data for this outcome measure was reported for overall participants.
|
Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
|
Transferrin Values
Periodo de tiempo: Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
|
Transferrin levels were measured as milligram/deciliter (mg/dL).
Data for this outcome measure was reported for overall participants.
|
Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
|
Transferrin Saturation Values
Periodo de tiempo: Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
|
Transferrin saturation (TSAT) measured as a percentage, is a medical laboratory test.
It is the ratio of serum iron and total iron-binding capacity, multiplied by 100.
Data for this outcome measure was reported for overall participants.
|
Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
|
C-reactive Protein (CRP) Values
Periodo de tiempo: Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
|
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay.
A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Data for this outcome measure was reported for overall participants.
|
Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
|
Number of Physicians Satisfied With Treatment at Final Visit
Periodo de tiempo: Month 12 or early discontinuation
|
Physicians were asked to rate their satisfaction with the methoxy polyethyleneglycol-epoetin beta treatment at final visit.
Physicians' responses were "very satisfied", "satisfied", "undecided", or "not satisfied".
One physician could analyze multiple participants but for the purpose of analysis each physician was counted as one for each analyzed participants; hence, the number of physicians (as per this assessment) was equal to the number of participants analyzed.
Data for this outcome measure was reported for overall participants.
|
Month 12 or early discontinuation
|
Number of Participants Who Continued Treatment With Methoxy Polyethyleneglycol-epoetin Beta After Study Completion
Periodo de tiempo: Month 12 or early discontinuation
|
At final visit, physicians were asked to answer ("yes" or "no") the question, whether they would continue treatment with methoxy polyethyleneglycol-epoetin beta treatment after study completion.
Data for this outcome measure was reported for overall participants.
|
Month 12 or early discontinuation
|
Number of Participants With Reasons for Discontinuation of Methoxy Polyethyleneglycol-epoetin Beta Treatment After Study Completion
Periodo de tiempo: Month 12 or early discontinuation
|
At final visit, physicians were asked to state the reasons in case of discontinuation of treatment with methoxy polyethyleneglycol-epoetin beta.
The same participant could have discontinued treatment due to multiple reasons.
Data for this outcome measure was reported for overall participants.
|
Month 12 or early discontinuation
|
Number of Participants Who Switched to Other Erythropoiesis Stimulating Agents (ESA)-Therapy
Periodo de tiempo: Month 12 or early discontinuation
|
Number of participants who switched to other ESA therapies including Aranesp, Biopoin, Biosimilar, Erypo, and NeoRecormon is presented.
Data for this outcome measure was reported for overall participants.
|
Month 12 or early discontinuation
|
Number of Participants Satisfied With Treatment at Final Visit
Periodo de tiempo: Month 12 or early discontinuation
|
Participants were asked to rate their satisfaction with methoxy polyethyleneglycol-epoetin beta treatment at final visit.
Participants' responses were "very satisfied", "satisfied", "undecided", or "not satisfied".
Data for this outcome measure was reported for overall participants.
|
Month 12 or early discontinuation
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Average Methoxy Polyethylene Glycol-epoetin Beta Dose
Periodo de tiempo: Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
|
Average methoxy polyethylene glycol-epoetin beta dose per application is presented by study month.
Mean values were taken when more than 1 application was documented for a participant during the time period considered.
Data for this outcome measure was reported for overall participants.
|
Months 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de marzo de 2010
Finalización primaria (Actual)
1 de febrero de 2013
Finalización del estudio (Actual)
1 de febrero de 2013
Fechas de registro del estudio
Enviado por primera vez
15 de enero de 2010
Primero enviado que cumplió con los criterios de control de calidad
15 de enero de 2010
Publicado por primera vez (Estimar)
18 de enero de 2010
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
18 de diciembre de 2015
Última actualización enviada que cumplió con los criterios de control de calidad
17 de noviembre de 2015
Última verificación
1 de noviembre de 2015
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- ML22714
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .